DSP107

BIOLOGICAL2 trials

Sponsors

Kahr Medical

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorChronic Myelomonocytic LeukemiaColorectal CancerMyelodysplastic SyndromesNon Small Cell Lung Cancer

Phase 1

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Active, not recruitingNCT04440735

Kahr MedicalAdvanced Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer

Start: 2020-10-07End: 2025-09-30Target: 125Updated: 2025-01-09

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

TerminatedNCT04937166

Kahr MedicalAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2022-01-13End: 2025-10-24Updated: 2025-11-07

Related Papers

Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.

Journal of Clinical Oncology2025-05-281 citations

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-012 citations

Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-015 citations